Company intelligence / Profile preview
PrecisemAb Biotech
Kaohsiung, Kaohsiung City, Taiwanprecisemab.com.tw ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
PrecisemAb’s Universal Antibody Lock platform enables the creation of conditionally active antibody drugs that are only activated in diseased tissue. This approach aims to reduce on-target toxicity and systemic side effects. Their lead program PSM101 targets EGFR-expressing tumors and has shown promising animal data; non-human primate safety studies were planned for early 2024. The company also develops ADCs and immunotherapies using this masking technology. No clinical trial results have been reported yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- monoclonal antibodies (mAbs)antibody-drug conjugates (ADCs)bispecific antibodiesconditionally active ("locked") antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
GlycoNex—technology licensing agreement to develop anti-glycan antibodies using UAL platform for solid tumorsAcademic origin from Kaohsiung Medical UniversityEngages in co-development/licensing partnerships with global pharma companies
Beyond the preview
Go deeper on PrecisemAb Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PrecisemAb Biotech.